Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies
- 1Department of Children Hematological Oncology, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, No.25, Taiping Street, Jiangyang District, Luzhou, Sichuan 646000 China
Abstract
Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy in children, with molecular alterations playing critical roles in disease development and therapeutic responses. The CBFA2T3::GLIS2 (C/G) is the most frequent genetic alteration identified in non-Down syndrome acute megakaryoblastic leukemia (AMKL) and results from a cryptic inversion involving the subtelomeric region of chromosome 16. Multiple chimeric transcripts can be generated depending on the breakpoint location, with CBFA2T3-ex11/GLIS2-ex3 being the predominant transcript. This fusion gene is associated with chemotherapy resistance and an unfavorable clinical outcome. Although initially identified in AMKL, it has also been detected in several cytogenetically normal AML subtypes, including M0, M1, M2, M4, and M5. However, the molecular mechanisms underlying C/G fusion-driven leukemogenesis remain incompletely characterized. This review provides an overview of the pathogenic mechanisms, emerging therapeutic strategies, and clinical challenges associated with C/G-positive pediatric AML.
Related
- Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
- Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
- Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies
- Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
BibTeX
@article{she2026advances,
title = {{Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies}},
author = {Jiatong She and Ling Guo and You Yang and Jing Liu and Rui Zhang and Yan Liu and Huazhang Guo and Yangyang Huang and Wenjun Liu},
journal = {Annals of Hematology},
year = {2026},
month = aug,
doi = {10.1007/s00277-026-07227-2},
url = {https://doi.org/10.1007/s00277-026-07227-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies
AU - Jiatong She
AU - Ling Guo
AU - You Yang
AU - Jing Liu
AU - Rui Zhang
AU - Yan Liu
AU - Huazhang Guo
AU - Yangyang Huang
AU - Wenjun Liu
PY - 2026
DA - 2026/08/13
JO - Annals of Hematology
DO - 10.1007/s00277-026-07227-2
UR - https://doi.org/10.1007/s00277-026-07227-2
AB - Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy in children, with molecular alterations playing critical roles in disease development and therapeutic responses. The CBFA2T3::GLIS2 (C/G) is the most frequent genetic alteration identified in non-Down syndrome acute megakaryoblastic leukemia (AMKL) and results from a cryptic inversion involving the subtelomeric region of chromosome 16. Multiple chimeric transcripts can be generated depending on the breakpoint location, with CBFA2T3-ex11/GLIS2-ex3 being the predominant transcript. This fusion gene is associated with chemotherapy resistance and an unfavorable clinical outcome. Although initially identified in AMKL, it has also been detected in several cytogenetically normal AML subtypes, including M0, M1, M2, M4, and M5. However, the molecular mechanisms underlying C/G fusion-driven leukemogenesis remain incompletely characterized. This review provides an overview of the pathogenic mechanisms, emerging therapeutic strategies, and clinical challenges associated with C/G-positive pediatric AML.
SN - 0939-5555
SN - 1432-0584
ER -